Verastem Enters Critical Trial for a New Pancreatic Cancer Weapon

BOSTON, MA – June 16, 2026 – In the relentless battle against pancreatic cancer, one of the most lethal malignancies, glimmers of progress are measured in milestones. Verastem Oncology just marked a significant one, announcing the first patient has been dosed in a pivotal Phase 2 trial for its investigational drug, VS-7375. This isn't just another clinical trial; it's a registration-directed study, a regulatory signal that this therapy could be on an accelerated path to patients who have precious few options.

The trial, TARGET-D 201, zeroes in on patients with metastatic pancreatic ductal carcinoma (mPDAC) harboring a specific genetic flaw: the KRAS G12D mutation. This move places Verastem at the sharp end of precision oncology, tackling a long-undruggable target that drives a significant portion of these deadly tumors.

A Formidable Foe Meets a Novel Mechanism

To understand the significance of this trial, one must first grasp the grim reality of its target. Pancreatic cancer carries a five-year survival rate of just 3% for metastatic disease. A key culprit behind its aggression and treatment resistance is the KRAS gene. Mutations in KRAS are found in over 90% of pancreatic cancers, and the G12D variant is the most common, present in roughly 40% of all cases. For decades, this mutation was considered "undruggable" due to the protein's smooth, almost featureless structure, which lacked clear pockets for drugs to bind.

Verastem's VS-7375 represents a new wave of attack. It is designed as a dual ON/OFF inhibitor. Most KRAS proteins cycle between an active 'ON' state and an inactive 'OFF' state. Many competing drugs are designed to bind to only one of these states. VS-7375, however, is engineered to bind to both. The strategic rationale is compelling: by blocking the protein in both its active and inactive forms, the drug could achieve a more complete and durable shutdown of the cancer-driving signals. Preclinical data suggests this dual-action approach leads to more profound and sustained tumor regression compared to single-state inhibitors.

“Dosing the first patient in the TARGET-D 201 trial marks an important milestone in the development of VS-7375 for patients with KRAS G12D-mutated metastatic pancreatic cancer, where unmet need remains high,” said Michael Kauffman, M.D., Ph.D., president of development at Verastem Oncology.

Navigating a Crowded and Competitive Field

Verastem is not alone in the hunt for a KRAS G12D inhibitor. The field is a hotbed of biotech innovation, with major players like Mirati/BMS and Revolution Medicines, as well as emerging companies, all vying to crack this lucrative and medically critical target. This competitive pressure makes Verastem's strategy and execution paramount.

The company is moving aggressively, with three registration-directed Phase 2 trials for VS-7375 running concurrently in pancreatic, non-small cell lung, and colorectal cancers. This multi-pronged approach diversifies risk and maximizes the potential market for the drug. Further bolstering its position, Verastem has secured FDA Fast Track Designation for VS-7375 in both pancreatic and lung cancer. This designation is more than a procedural perk; it validates the significant unmet need and the drug's potential to address it, enabling more frequent communication with the FDA and eligibility for accelerated approval and rolling review.

This regulatory tailwind is crucial. A 'registration-directed' trial design implies that, should the data be strongly positive, this Phase 2 study could form the primary basis for a marketing application, potentially shaving years off the traditional drug development timeline. For patients with a median survival measured in months, this acceleration is everything.

The Corporate and Clinical Strategy

Executing such an ambitious clinical program requires significant capital. Verastem appears well-positioned, with a reported cash runway into the first half of 2027, bolstered by revenue from its already-marketed drug, AVMAPKI® FAKZYNJA® CO-PACK. The company's strategic acumen is also on display in its partnership with GenFleet Therapeutics, from whom it licensed VS-7375 in January 2025. This deal provided Verastem with a promising, de-risked clinical asset without the time and expense of early-stage discovery.

The TARGET-D 201 trial itself reflects a thoughtful clinical strategy. It will evaluate VS-7375 not only as a monotherapy but also in combination with cetuximab. Furthermore, its exploration in the first-line setting represents a bold push toward a potential chemotherapy-free regimen—a paradigm shift that would be transformative for patient quality of life. As the trial progresses, the entire oncology community will be watching to see if this dual-action inhibitor can finally turn the tide against one of cancer's most challenging mutations.